FDA needs three more months to review Roche's SMA drug — giving Biogen, Novartis some relief
The first oral drug for spinal muscular atrophy was widely expected to be approved by the end of May after priority review. But its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
